Research Leadership Australasian Leukaemia & Lymphoma Group is a well-established research organization with a history dating back to 1973, demonstrating long-term experience and credibility in clinical trials for blood cancers, making it a reliable partner for innovative healthcare solutions.

Innovative Data Assets The organization's National Blood Cancer Registry, holding Australia's largest real-world AML data, offers a valuable asset for companies developing diagnostics, therapies, or data analytics tools tailored to blood cancer treatments.

Active Industry Engagement Participation in prominent industry events like ASH 2025 and Blood 2025 Conference indicates strong networking and visibility within the blood cancer research community, providing opportunities for strategic collaborations and sponsorship.

Collaborative Projects Recent partnerships, such as the collaboration with Mendus AB to study AML treatments, showcase the company’s openness to innovative clinical trials, presenting an opportunity for companies offering novel therapies or research technologies to collaborate.

Funding & Growth With revenues between one to ten million dollars, the organization shows healthy growth potential, presenting opportunities for targeted funding, grants, or partnership investments to expand research capabilities and accelerate clinical development.